OpenLobby.EU
Explore

GLOBAL HEALTH ADVOCATES

GHA

Global Health Advocates is an NGO promoting health as a human right and addressing global health inequalities.

Lobbying Activity

Meeting with Ingrid Keller (Head of Unit Health and Food Safety) and Pasteur Network

12 Dec 2025 · Presentation of the report “No eradication without innovation: the EU at a crossroads to eliminate HIV/AIDS, TB, and malaria”.

Global Health Advocates urges €200 billion for EU external action

28 Nov 2025
Topic — The EU is planning its long-term budget for international development and cooperation.
Message — The organization demands a €200.3 billion minimum budget for the Global Europe Instrument to maintain credible global influence. They want mandatory spending targets for human development, climate, and gender equality while rejecting aid conditionality linked to migration.123
Why — Ring-fenced spending targets guarantee sustained funding for the organization's health and development priorities.4
Impact — Private companies would lose access to large, direct grants currently lacking oversight or competition.5
Read full response

Meeting with Cecile Billaux (Head of Unit Directorate-General for International Partnerships) and Stichting Aidsfonds - Soa Aids Nederland and Amis du Fonds Mondial Europe

2 Apr 2025 · Exchange of views about the exhibition “Healthy Lives: The Power of the EU’s Investments in Global Health,” March 18 to 20 at the European Parliament and the civil society requests associated to it; other potential events

Meeting with Christine Singer (Member of the European Parliament, Shadow rapporteur)

25 Mar 2025 · Sustainable Development Goals

Meeting with Martin Seychell (Deputy Director-General Directorate-General for International Partnerships) and

19 Mar 2025 · Current global health context

Meeting with Murielle Laurent (Member of the European Parliament) and ACTION CONTRE LA FAIM and Coordination SUD

4 Dec 2024 · Evenement Agir pour l'Avenir

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen) and The ONE Campaign

16 Jul 2024 · to discuss how the EU can step up its efforts and support GAVI in the context of the GAVI replenishment

Meeting with Tilly Metz (Member of the European Parliament)

22 Jan 2024 · Global Health

Meeting with Ilan De Basso (Member of the European Parliament) and Save the Children Europe and

30 May 2023 · Möte

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen)

5 May 2023 · exchange on ongoing health issues

Meeting with Kathleen Van Brempt (Member of the European Parliament, Committee chair)

2 Mar 2023 · Redaction of vaccine contracts

Meeting with Marc Botenga (Member of the European Parliament) and Médecins du monde Belgique and

25 Jan 2023 · Covi committee

Meeting with Sara Cerdas (Member of the European Parliament) and European Public Health Alliance and

20 Jan 2023 · COVI Committee hearings and report

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen) and OXFAM INTERNATIONAL EU ADVOCACY OFFICE and

9 Nov 2022 · Global Health Strategy

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen) and Save the Children Europe and

29 Mar 2022 · Global Health

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen)

20 Jan 2022 · EU-Africa Summit

Meeting with Diana Montero Melis (Cabinet of Commissioner Jutta Urpilainen) and World Vision Brussels & EU Representation ivzw/aisbl and

27 Oct 2021 · UN Food System Summit and Nutrition for Growth Summit

Meeting with Lora Borissova (Cabinet of Commissioner Jutta Urpilainen), Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen) and

8 Oct 2021 · Africa-EU partnership

Meeting with Jutta Urpilainen (Commissioner) and OXFAM INTERNATIONAL EU ADVOCACY OFFICE and

25 May 2021 · Roundtable on Human Development

Global Health Advocates urge EU focus on neglected diseases

9 Apr 2021
Topic — The consultation reviews the EU global strategy for research, innovation, and education.
Message — They request more funding for neglected diseases and mental health. Civil society should help co-define research priorities with affected countries. EU funding must include binding rules to ensure open access.123
Why — This would increase the organization's influence over international health research priorities.4
Impact — Commercial pharmaceutical companies could lose profits due to mandatory open access rules.5
Read full response

Meeting with Ines Prainsack (Cabinet of Commissioner Stella Kyriakides)

12 Mar 2021 · Exchange on EU global solidarity, COVAX and EU pledges

Global Health Advocates calls for independent EU health agency

24 Feb 2021
Topic — This consultation explores establishing an EU authority to coordinate responses to health emergencies.
Message — The group wants an independent agency excluding industry from governance. They demand public ownership of research and transparent contracts.123
Why — This approach ensures public investments lead to affordable, accessible medical products.4
Impact — Pharmaceutical companies would lose their policy influence and control over patents.5
Read full response

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen) and Save the Children Europe and

11 Sept 2020 · EU Global Health Strategy

Meeting with Diana Montero Melis (Cabinet of Commissioner Jutta Urpilainen) and Save the Children Europe and

2 Apr 2020 · nutrition in partner countries

Meeting with Renaud Savignat (Cabinet of Commissioner Jutta Urpilainen) and Save the Children Europe and The ONE Campaign

17 Feb 2020 · discussion on pledging to GAVI

Response to EU-Africa Global Health Partnership

27 Aug 2019

The EU-Africa Global Health Partnership should remain a public-public partnership with a focus on neglected diseases - In order to retain its public health focus, the successor to EDCTP should not be changed to a 187 public-private partnership. Funding should be accessible by industry and foundations, but they should not be included in the governance structures linked to agenda-setting or in the drafting of legal agreements related to IP and access provisions. [Evidence and evaluations from several of the existing 187s (in particular the health PPP IMI) indicate that private partners dominate the agenda-setting and governance (see IMI2 Interim Evaluation: https://ec.europa.eu/research/health/pdf/imi2_interim_evaluation.pdf) leading to poor outcomes for society as well as exploitation of weaker partners. (see IMI socio-economic impact assessment: https://www.imi.europa.eu/sites/default/files/uploads/documents/reference-documents/SocioeconomicImpactAssessment_FINALMay2016.pd)] - It should safeguard the equal partnership nature with sub-Saharan African countries as it contributes to closer collaboration, better implementation, network strengthening and capacity building. It should promote high standards of transparency at all levels. - The EU-Africa Global Health Partnership should also retain its public health focus and not add the objective of improving the competitiveness of industry. It should retain its focus on poverty-related and neglected infectious diseases affecting vulnerable and neglected populations, without diverting funding to other infectious diseases that do not suffer from market failure. Embed comprehensive and binding provisions on access - EDCTP2 is the only EU global health mechanism with the objective to help develop accessible, suitable, and affordable health tools for many PRNDs, however specific access provisions have been abolished. Binding provisions on how to ensure patients’ access to medical tools and access to research data should be in place in the next EU-Africa Global Health Partnership for all R&D projects funded through the EU. Firm requirements need to be in place from early and basic research onward so that publicly funded R&D will eventually lead to products that will benefit target populations, including those in resource-poor settings. This is vital to ensure that the outputs of EU-funded research directly impact global health, and to facilitate improved collaboration within consortia. - In order to increase the chances of life-saving breakthroughs, the research data and results of clinical trials should be made available and opt-outs should be strictly limited. Commit an ambitious budget to capitalise on past EU investments -Ensuring at least 1 billion euro EC contribution, as well as: - Increasing European participating states cash contributions - Encouraging greater co-investment from sub-Saharan African participating states through stronger governance and funding incentives - Expanding opportunities for (particularly cash) contributions from Foundations, not-for- profits, and private sector partners should be fostered
Read full response

Global Health Advocates demand end to industry research dominance

26 Aug 2019
Topic — This consultation concerns a new European partnership for collaborative research and innovation in healthcare.
Message — GHA proposes reducing industry presence on the governing board to ensure a stakeholder balance. They advocate for mandatory open access and equitable pricing for products resulting from public funding. The partnership should prioritize neglected diseases based on public health needs rather than commercial profitability.123
Why — This would secure greater decision-making power for civil society organizations in health policy.4
Impact — Major pharmaceutical corporations would lose their current dominant control over strategic research agendas.5
Read full response

Global Health Advocates urge prioritising societal impact in research

22 Aug 2018
Topic — A consultation on the rules and objectives of the Horizon Europe research programme.
Message — Societal impact based on global goals should take priority over industrial profit. They seek mandatory civil society involvement and guarantees for affordable medical products.123
Why — This would secure more funding and institutional influence for health-focused non-profit organizations.45
Impact — Pharmaceutical companies and industrial firms could face reduced profit margins from pricing rules.67
Read full response

Global Health Advocates Demands Societal Focus in EU Research

6 Aug 2018
Topic — This consultation concerns the specific programme for implementing the Horizon Europe research initiative.
Message — Global Health Advocates calls for civil society to be involved throughout the entire research cycle. They want safeguards to ensure public investments result in affordable products and maintain dedicated funding for societal engagement.123
Why — This proposal secures formal decision-making roles and guaranteed funding for civil society organizations.45
Impact — Profit-driven industries may face reduced funding and stricter controls on their commercial products.67
Read full response

Meeting with Annika Nowak (Cabinet of Commissioner Vytenis Andriukaitis) and European Public Health Alliance and DSW (Deutsche Stiftung Weltbevoelkerung)

18 Jul 2018 · Horizon Europe

Meeting with Robert Schröder (Cabinet of Commissioner Carlos Moedas)

22 Jun 2018 · Civil society reaction to Horizon Europe pillar structure

Meeting with Nils Behrndt (Cabinet of Vice-President Neven Mimica) and OXFAM INTERNATIONAL EU ADVOCACY OFFICE and

4 Oct 2017 · Financing for development cooperation

Meeting with Ivan Prusina (Cabinet of Vice-President Neven Mimica)

19 May 2017 · Discussion on Food and Nutrition Security

Meeting with Vytenis Andriukaitis (Commissioner) and

28 Nov 2016 · EU and NGOs action on HIV, TB and Hepatitis

Meeting with Nils Behrndt (Cabinet of Vice-President Neven Mimica) and OXFAM INTERNATIONAL EU ADVOCACY OFFICE and

18 Feb 2016 · Health in development cooperation

Meeting with Ivan Prusina (Cabinet of Vice-President Neven Mimica)

7 Dec 2015 · Discussion on the fulfilment of EU nutrition committments, as well as political vision of the European Commission in the run up to the second Nutrition for Growth Summit